NOXAFIL
What it isTriazole antifungal; prophylaxis in neutropenia and mucormycosis.
Why this oneThe broadest azole spectrum, covering Mucorales, which voriconazole does not.
What limits itA strong CYP3A4 inhibitor. The delayed-release tablet absorbs far better than the suspension and they are not interchangeable.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Prophylaxis of invasive Aspergillus and Candida infections | Adults | 300 mg BID ×1 day (load) | 300 mg QD | 300 mg QD |
| Prophylaxis of invasive Aspergillus and Candida infections | Peds 13 to <18 yr, >40 kg | 300 mg BID ×1 day (load) | 300 mg QD | 300 mg QD |
Renal No dosage adjustment; monitor closely for breakthrough fungal infections in severe renal impairment
Hepatic Undefined
Not substitutable with the oral suspension / PowderMix formulations
Pregnancy May cause fetal harm based on animal data (skeletal malformations)
Lactation No human data; present in rat milk
NO BOXED WARNINGS
Principal riskA strong CYP3A4 inhibitor; formulations are not interchangeable
Cost, est. cash$10–$300/month
Generic entry2019
Legacy pregnancy categoryC
Defining liabilityHepatotoxicity and clinically important CYP/QT interactions; organ toxicity varies markedly by agent.
